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Abstract At present, there are no validated methods to
identify persons who are at increased risk for Parkinson
Disease (PD) from the general population. We investigated
the clinical usefulness of a recently proposed non-motor
risk score for PD (the PREDICT-PD risk score) in the
population-based Rotterdam Study. At baseline (1990), we
constructed a weighted risk score based on 10 early non-
motor features and risk factors in 6492 persons free of
parkinsonism and dementia. We followed these persons for
up to 20 years (median 16.1 years) for the onset of PD until
2011. We studied the association between the PREDICT-
PD risk score and incident PD using competing risk
regression models with adjustment for age and sex. In
addition, we assessed whether the PREDICT-PD risk score
improved discrimination (C-statistics) and risk classifica-
tion (net reclassification improvement) of incident PD
beyond age and sex. During follow-up, 110 persons were
diagnosed with incident PD. The PREDICT-PD risk score
was associated with incident PD (hazard ratio [HR] =
1.30; 95 % confidence interval [1.06; 1.59]) and yielded a
small, non-significant improvement in overall discrimina-
tion (DC-statistic = 0.018[-0.005; 0.041]) and risk clas-
sification (net reclassification improvement = 0.172
[-0.017; 0.360]) of incident PD. In conclusion, the PRE-
DICT-PD risk score only slightly improves long-term
prediction of PD in the community.
Keywords Parkinson disease  Population-based  Risk
prediction  Risk factors
Introduction
Parkinson Disease (PD) is the second most common neu-
rodegenerative disorder among elderly [1]. At present, no
treatment can effectively modify disease progression in
patients with PD. This may be due to the advanced stage of
pathology that PD patients already have at the time of
clinical diagnosis [2]. The identification of persons from
the general population who are at high risk of PD might
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open the door to earlier diagnosis, and possibly enable
early symptomatic treatment. Equally important, it would
enable the selection of persons who, possibly after addi-
tional refined screening, can be enrolled in neuroprotective
trials.
In the most recent comprehensive meta-analysis of
nonmotor features and risk factors for PD to date, several
variables were determined to affect the risk of PD [3].
Subsequently, a cohort study in the United Kingdom was
initiated (PREDICT-PD) to assess the validity of a risk
score based on 11 of these variables to prospectively pre-
dict PD. In cross-sectional analyses at baseline, the PRE-
DICT-PD risk score was associated with several proxies for
PD [4]. However, the prospective usefulness of the PRE-
DICT-PD risk score for PD remains unclear.
In this study, we investigated the prospective prognostic
value of the PREDICT-PD risk score in an independent,
population-based sample with 20 years of follow-up.
Methods
Study design and setting
The study was embedded in the first subcohort of the
Rotterdam Study (RS-I), a large, prospective, population-
based study in the Netherlands [5, 6]. The study was ini-
tiated in 1990, inviting all inhabitants of Ommoord who
were aged C55 years. 7983 participants (78 %) agreed to
participate and provided written informed consent. At
baseline, participants were extensively screened for
parkinsonism and dementia, and assessments of nonmotor
features and risk factors used to derive the risk score were
conducted [7, 8]. For this report, we excluded persons with
prevalent parkinsonism or dementia and persons who were
not screened for both, leaving 6492 persons for analyses.
We followed participants for the development of PD from
baseline until: onset of parkinsonism, onset of dementia,
death or 1 January 2011, whichever came first. Until 2011,
the study has had a total of five visits, including four fol-
low-up visits. At each visit, participants underwent home
interviews and medical examinations at the research center.
Assessment of parkinsonism and PD
A detailed description of parkinsonism and PD assessment
methods has previously been published [9] and is sum-
marized in Online Resource 1. In short, we used four
overlapping modalities to screen for potential parkinsonism
during follow-up: in-person screening (on average every
4 years), in-person interviews, use of antiparkinson medi-
cation, and alerts from continuous monitoring of clinical
records. For each modality, the proportion of incomplete
data was small (range of averages:\1–12 %). Of all per-
sons who screened positive in any of these methods,
complete medical records (including letters from medical
records of specialists and general practitioners) were
studied and case reports were drawn up covering all
potentially relevant information to establish presence and
cause of parkinsonism. These case reports were evaluated
by a panel led by an experienced neurologist. PD was only
diagnosed after exclusion of secondary causes, and medical
records of all incident parkinsonism cases (both PD and
secondary) continued to be scrutinized until the end of the
study period for new information that could lead to a
revision of the diagnosis. Given the substantial overlap
between the four detection methods we considered persons
who were not screened in-person during one of the follow-
up rounds still at risk for parkinsonism and PD. For onset
of PD, we used the age at midpoint between the date on
which parkinsonism first was observed (either during in-
person screening or in medical records) and the preceding
in-person examination. Person-time at risk for incident PD
ended at onset of parkinsonism, incident dementia (date of
clinical diagnosis), death, or January 1, 2011.
Assessment of nonmotor features and risk factors
in the PREDICT-PD risk score
Nonmotor features and risk factors used to derive the risk
score were assessed during the baseline home interview and
center visits. Smoking habits were assessed during home
interviews and participants were subsequently categorized
as current, former and never smokers. Coffee and alcohol
intake were assessed using food-frequency questionnaires.
In addition, participants were asked whether any of their
parents, siblings or children had PD. Participants were also
asked:’’Did you ever have a serious head trauma or a con-
cussion?’’ and ‘‘Did you ever have periods of depression?’’.
During home interviews, participants were questioned
for current medication they were using at the time. This
included laxative medication, non-steroidal anti-inflam-
matory drugs (NSAIDs), calcium-channel blockers, beta-
blockers, and other antihypertensive drugs (ATC-codes
C02, C03, C07, C08, and C09). Since we had no data
available on stool frequency, we considered use of laxative
medication as a proxy for constipation. Blood pressure was
measured twice during center visits, and hypertension was
diagnosed if the mean of two measurements exceeded
140/90 mmHg or if a person used antihypertensive medi-
cation with an adequate indication.
We had no data on erectile dysfunction and conse-
quently excluded erectile dysfunction from the risk score.
In the meta-analysis, farming occupation, rural living,
pesticide exposure, and well-water drinking were also
identified as risk factors [3], but these factors were not
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included in the PREDICT-PD risk score [4]. In the Rot-
terdam Study, only 5 study participants (\0.1 %) worked
as a farmer (none of whom developed PD during follow-
up), and all study participants lived in a non-rural, subur-
ban district (i.e., Ommoord). We lacked information on
pesticide exposure and well-water drinking.
Statistical analysis
We constructed a risk score for each individual, by adding
up their number of risk factors weighted by the log-trans-
formed, reported risk-increasing or (inverted) risk-de-
creasing effect size for the association with PD [3]. Risk
scores were transformed into z-scores to facilitate evalua-
tion of their effect per standard deviation increase. A
higher risk score corresponds to a larger weighted number
of risk factors and thus a higher expected risk of PD. We
constructed two models: model I comprised age and sex for
overall analyses, and only age for sex-stratified analyses.
Model II comprised model I plus the PREDICT-PD risk
score. We visually inspected reclassification of risk after
addition of the PREDICT-PD risk score using a reclassi-
fication scatterplot [10].
We investigated the association between the risk score
and incident PD by comparing model II to model I using
the method proposed by Fine and Gray, which takes into
account the risk of competitive events (i.e., incident
dementia or death) [11]. We examined the interaction term
of the PREDICT-PD risk score with sex, and subsequently
stratified analyses by sex. The discriminative value of both
models was expressed with Uno’s C-statistic, which takes
into account right-censoring [12]. To study reclassification,
we calculated the continuous net reclassification improve-
ment (NRI) [13]. Since the predictive power of dependent-
state risk factors may decrease over time, we repeated our
prediction analyses after restriction of follow-up to the first
5 and 10 years, respectively.
We had complete data on 91 % of predictor values
(missing values between 0 and 19 % per predictor).
Missing values were handled by multiple imputation using
the mean of five imputations, based on age, sex and all
other nonmotor predictors.
Results
The most prevalent nonmotor risk factors were coffee and
alcohol use, while constipation and a family history of PD
were the least prevalent (Table 1). During follow-up
(87,321 person-years, median 16.1 years), 110 individuals
had incident PD (age-adjusted incidence rate 1.4 per 1000
person-years) of whom 56 were men and 54 were women.
In total, 3713 persons died, and 1021 were diagnosed with
incident dementia while at risk of parkinsonism. In our
population, the only risk factors that were independently
associated with incident PD were current smoking, former
smoking and depression (Table 1). As shown in Online
Resource 2, women had effect estimates of laxative use,
family history, hypertension, NSAID use, CCB use, and
alcohol for incident PD that were direction-consistent with
the meta-analysis, whereas men had opposite estimates.
Furthermore, we observed a significant association
between family history and incident PD in women, but not
in men.
Predicted 20-year risk of PD ranged from 0.7 to 18.8 %
in model I (median 2.2 %), and from 0.5 to 22.5 % (me-
dian 2.2 %) in model II (Fig. 1). During follow-up, persons
in the highest PREDICT-PD risk score tertile consistently
had the highest cumulative hazard of incident PD (Online
Resource 3). The PREDICT-PD risk score was indepen-
dently associated with incident PD and yielded a small,
non-significant improvement in discrimination of incident
PD beyond age and sex (Table 2; DC = 0.018 [-0.005;
0.041]). Compared to model I, model II slightly improved
overall classification of PD risk.
The association between the PREDICT-PD risk score
and incident PD was strongly modified by sex (p = 0.004).
Stratified analyses showed that the risk score was associ-
ated with incident PD independently of age in women but
not in men. In line with this, risk prediction of PD based
solely on age was more accurate in men than in women, but
this difference faded after application of the PREDICT-PD
risk score. Classification of PD risk was improved by
model II in women, but not in men.
After restriction of follow-up to 5 years, discrimination
and risk classification of incident PD did not significantly
improve (DC = 0.008 [-0.022; 0.037] and risk classifi-
cation (NRI = 0.012 [-0.091; 0.145]) from model I to II.
Similarly, after restriction of follow-up to 10 years, pre-
diction did not improve (DC = 0.013 [-0.011; 0.038] and
NRI = 0.031 [-0.069; 0.140]).
Discussion
In this prospective, population-based sample with 20 years
of follow-up, we found that the PREDICT-PD risk score
yielded a small, non-significant improvement in overall
discrimination and classification of incident PD. This was
due to improvement of PD risk prediction in women to the
level of men.
At present, there are no validated methods to identify
persons at high risk for PD from the general population so
that they can be monitored for onset of symptoms or
enrolled in neuroprotective trials. The recently proposed
PREDICT-PD risk score was based on a meta-analysis of
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early nonmotor features and risk factors [3, 4]. Strengths of
our study were its prospective design and inclusion of
community-dwelling individuals irrespective of PD risk.
Compared to cross-sectional case–control data, such as
from the multi-center Parkinson’s Progression Marker
Initiative [14], prospective community-based studies such
Table 1 Overview of population characteristics
Characteristic N in the Rotterdam study Reported RR/ORa HR (95 % CI) in the
Rotterdam study
Age at baseline, mean, y (SD) 68.7 (8.7) – 1.03 (1.01; 1.05)
Women (%) 3818 (58.8) – 0.39 (0.24; 0.62)
Smoking (%)
Never 2202 (34.6) 1.00
Former 2695 (42.4) 0.78 0.53 (0.32; 0.89)
Current 1463 (23.0) 0.44 0.36 (0.19; 0.67)
Family history (%)b 311 (5.0) 4.45 1.62 (0.80; 3.27)
Coffee (%) 5087 (97.2) 0.67 1.78 (0.38; 8.27)
Alcohol (%) 4154 (79.4) 0.90 0.87 (0.52; 1.44)
Hypertension (%) 3572 (55.0) 0.74 1.13 (0.74; 1.73)
NSAID use (%) 512 (7.9) 0.83 1.14 (0.58; 2.24)
CCB use (%) 388 (6.0) 0.90 1.42 (0.75; 2.69)
Beta-blocker use (%) 948 (14.6) 1.28 1.20 (0.72; 2.00)
Constipation (%) 237 (3.7) 2.34 1.35 (0.58; 3.13)
Head injury (%) 1980 (30.5) 1.58 0.77 (0.51; 1.18)
Self-reported periods of depression (%) 2028 (33.2) 1.86 1.63 (1.10; 2.42)
N number of persons at risk for Parkinson Disease, RR relative risk, OR odds ratio, HR hazard ratio adjusted for age, sex and all other risk factors,
95 % CI, 95 % confidence interval. y year, SD standard deviation, NSAID non-steroidal anti-inflammatory drug, CCB calcium channel blocker
For constipation, a proxy was used (use of laxative medication)
a Reported in the meta-analysis of early nonmotor features and risk factors by Noyce et al. [3]. Of note, no relative risks or odds ratios were
reported for age and sex
b History of Parkinson Disease in parents, siblings or children
Fig. 1 Reclassification scatterplot of the 20-year risk of incident
Parkinson Disease after addition of the PREDICT-PD risk score.
Model I, overall: age and sex. Model II, overall: age, sex and
PREDICT-PD risk score. a Persons without incident Parkinson
Disease. b Persons with incident parkinson disease
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as the Rotterdam Study have the advantage that all par-
ticipants (i.e., both PD future cases and controls) were
included and followed up using the same methodology,
presumably ensuring a realistic estimate of the risk of
incident PD in the general population. Further strengths
include long duration of follow-up for PD (median
16.1 years) and standardized assessment of PD diagnosis.
In addition, our sample was completely independent of
discovery samples used for relative risk estimates in the
meta-analysis [3].
Limitations included lack of data on erectile dysfunction
as well as the assessment of head trauma and depression
using a single question. In addition, we used laxative
medication as a proxy for constipation, which likely caused
a severe underestimate of the true prevalence of constipa-
tion, since many people who suffer from constipation do
not use drugs and change their dietary and lifestyle habits.
In our sample, only a small proportion of male participants
who did not develop incident PD and not a single male
incident PD patient used laxatives at baseline, suggesting
that our underestimate may have been larger in men than in
women. If we would have had complete information on
these factors, the PREDICT-PD risk score may have
improved PD prediction significantly in our population.
Furthermore, we lacked histologic confirmation of PD
diagnosis, which may have introduced non-differential
misclassification of PD cases. Also, we may have been
underpowered to detect a small significant improvement in
PD prediction, especially in the middle-long term (i.e.,
5 years) The estimates used in the PREDICT-PD risk score
were mostly based on studies that did not assess the
majority of variables simultaneously, and the estimates
were not sex-specific. In our sample, only 3 risk factors
were independently associated with incident PD (current
smoking, former smoking and depression), which may
indicate that the meta-analyzed estimates were inflated due
to limitations of the meta-analysis, such as publication bias,
a substantial degree of selection in some discovery sam-
ples, or insufficient adjustment for covariates [3]. Alter-
natively, we may have been underpowered to detect
significant associations with PD for separate risk factors,
and limitations in our assessment methods may have led to
underestimates of true associations. Future collaboration
across cohort studies who have prospectively assessed
(nearly) all risk variables in the score will probably
increase the accuracy of risk estimates. Similarly, while we
observed clear sex differences in associations between risk
factors and incident PD, most of the sex-specific associa-
tions in our sample were non-significant. Collaborative
studies may distinguish true sex differences from limita-
tions in assessment methods that may have worse in men
(e.g., laxative use).
Future studies can further build on the PREDICT-PD
risk score by focusing on three other key aspects. First,
some relatively common nonmotor risk factors for PD were
not yet part of the risk score, such as impaired olfactory
function [15]. Recently, dedicated olfactory function test-
ing was shown to distinguish patients with a PD diagnosis
from controls with very high accuracy [14]. Although the
long-term prospective predictive value of olfactory testing
for PD in the community has not yet been demonstrated
empirically, a previous study showed that impaired olfac-
tion is associated with PD up to 4 years before clinical
diagnosis [15]. Therefore, inclusion of prospective mea-
sures of olfactory function in the risk score may further
improve prediction of PD in the community. Second, while
the Rotterdam Study comprises a suburban-based study
population with only few farmers, discrimination and
classification accuracy in other communities may be
improved by inclusion of data on rural living and farming
occupation. Third, motor features were not included in the
risk score. Even in the absence of objective signs on rou-
tine screening, prediagnostic PD patients have subjective
parkinsonian complaints more frequently than controls
[16], and tremor is the most common presentation of PD
patients in primary care practice 10 years before clinical
diagnosis [17]. The advancement of dedicated motor
screening tests might not only lead to reliably detection of
PD in select subgroups of very high-risk persons (e.g.,
Table 2 PREDICT-PD risk score and the 20-year risk of incident
Parkinson Disease
Group Model Association Discrimination Reclassification
HR
[95 % CI]
C-statistic
[95 % CI]
NRI
[95 % CI]
Overall I (Reference) 0.649
[0.592; 0.707]
(Reference)
II 1.30
[1.06; 1.59]
0.667
[0.609; 0.725]
0.172
[-0.017; 0.360]
Men I (Reference) 0.684
[0.617; 0.752]
(Reference)
II 0.90
[0.63; 1.30]
0.681
[0.605; 0.758]
-0.105
[-0.356; 0.145]
Women I (Reference) 0.604
[0.530; 0.677]
(Reference)
II 1.70
[1.36; 2.12]
0.674
[0.602; 0.746]
0.461
[0.202; 0.721]
Model I, overall: age and sex. Model I, stratified analyses by sex: age
Model II, overall: age, sex and PREDICT-PD risk score. Model II,
stratified analyses by sex: age and PREDICT-PD risk score
HR hazard ratio for incident Parkinson Disease per standard deviation
in risk score. CI confidence interval. NRI, continuous net reclassifi-
cation improvement (model I is reference)
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RBD-patients [18]), but potentially also in community-
dwelling persons.
In conclusion, the PREDICT-PD risk score is a small
step forward towards predicting incident PD in the com-
munity, in particular in women, but there is still a clear
need for improvement.
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